CREBBP and neoplasm: Assuming CREBBP mutations were heterozygous (expected VAF 0.5) similarly to RSTS patients, given the VAFs (0.17 and 0.27) a quarter to about half of the cells were mutated for CREBBP. In addition to SNVs, tumor T48 had a heterozygous focal SCNA loss at 16p13.3 covering CREBBP exclusively.